|
|
|
| Effect of Zhuangfang Ruogan Huaxian Granules in the treatment of ascites due to hepatitis B cirrhosis with syndrome of liver-kidney yin deficiency |
| WU Shanshan1 LYU Yanhang1 WANG Zhenchang2▲ FU Yanqing1 CHEN Meicen1 LYU Huanghua1 |
1.Graduate School, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530222, China;
2.Department of Spleen， Stomach and Liver Disease, Guangxi International Zhuang Medical Hospital, Guangxi Zhuang Autonomous Region, Nanning 530201, China |
|
|
|
Abstract Objective To observe effect of Zhuangfang Ruogan Huaxian Granules in the treatment of ascites due to hepatitis B cirrhosis with syndrome of liver-kidney yin deficiency. Methods From February 2017 to February 2019, 70 patients with hepatitis B cirrhosis ascites with syndrome of liver-kidney yin deficiency were selected from the First Affiliated Hospital of Guangxi University of Chinese Medicine and Hepatology Department of Guangxi International Zhuang Medical Hospital. They were divided into control group and observation group according to the random number table method, with 35 cases in each group. Control group received routine medical treatment, while observation group received Zhuangfang Ruogan Huaxian Granule on the basis of control group. Total effective rate after treatment, traditional Chinese medicine syndrome score, liver function index, body mass, abdominal circumference and 24 h urine volume before and after treatment were compared between two groups. Results Total clinical effective rate of observation group was higher than that of control group (P < 0.05). The scores of jaundice, anorexia, abdominal distention, diarrhea, hepatosplenomegaly in two groups after treatment were lower than those before treatment, observation group was lower than control group, and the differences were statistically significant (P < 0.05). The levels of AST, ALT and TBIL in two groups after treatment were lower than those before treatment, and the level of ALB in observation group after treatment was higher than that before treatment, and the improvement in observation group was more significant than that in control group, and the differences were statistically significant (P < 0.05). Compared with those before treatment, body mass in the two groups decreased, abdominal circumference reduced, and 24 h urine volume increased after treatment, and the improvement in observation group was more significant than that in control group, and the differences were statistically significant (P < 0.05). Conclusion Zhuangfang Ruogan Huaxian Granules can obviously improve the therapeutic effect and improve the liver function and quality of life of patients with ascites due to hepatitis B cirrhosis with syndrome of liver-kidney yin deficiency.
|
|
|
|
|
|
[1] Kim TH，Ku DH，Um SH，et al. How can we improve the performance of model for end-stage liver disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment? [J]. J Gastroenterol Hepatol，2018，33（9）：1641-1648.
[2] Huang J. Evaluation of infection in patients with chronic hepatic disease [J]. Chin Med J，2017，130（2）：149-154.
[3] 王贵强.慢性乙型肝炎防治指南（2015年版）[J].实用肝脏病杂志，2016，19（3）：389-400．
[4] 中华中医药学会脾胃病分会，张声生，王宪波.肝硬化腹水中医诊疗专家共识意见（2017）[J].中华中医药杂志，2017，32（7）：3065-3068.
[5] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994.
[6] Chen C，Chen DP，Gu YY，et al. Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis：possible associations with ascites and hepatitis B viral factors? [J]. Tumour Biol，2015，36（8）：6255-6263.
[7] Zhang X，Wang SZ，Zheng JF，et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients [J]. World J Gastroenterol，2014，20（32）：11400-11405.
[8] Yue-Meng W，Li YH，Wu HM，et al. Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt：risk factors，warfarin efficacy，and clinical outcomes [J]. Clin Appl Thromb Hemost，2018，24（3）：462-470.
[9] 胡大山，胡建强，刘欢，等.肝硬化腹水患者的临床特征新趋势[J].肝脏，2019，24（2）：181-184.
[10] 苏洪佳，陈国忠，谢君艳.从中医脾虚“不能散精”论治肝硬化腹水[J].辽宁中医杂志，2019，46（1）：61-62.
[11] 崔璀，张志勇，薛敬东.一贯煎合猪苓汤联合西药治疗肝肾阴虚型肝硬化腹水临床观察[J].新中医，2017，49（2）：51-54.
[12] 李自强.养阴利水法治疗肝肾阴虚型顽固性肝硬化腹水32例[J].陕西中医，2009，30（9）：1119-1120.
[13] Wang C，Yang S，Huang J，et al. Activation of corticotropin releasing factor receptors up regulates collagen production by hepatic stellate cells via promoting p300 expression [J]. Biol Chem，2016，397（5）：437-444.
[14] 王振常，朱智德，杨删，等.柔肝化纤颗粒对肝纤维化大鼠ACTA表达的影响[J].时珍国医国药，2012，23（11）：2705-2707.
[15] 黄晶晶，黄鸿娜，王振常，等.柔肝化纤方联合腹水超滤浓缩回输术治疗肝硬化腹水40例临床观察[J].河北中医，2014，36（10）：1492-1495.
[16] 王露，陈英杰，彭立生，等.麝黄膏敷脐联合中药口服辅助治疗肝硬化腹水的临床效果[J].世界中医药，2018， 13（2）：352-355.
[17] 吴华清，孙晓伟，王焕英，等.消瘀降浊汤治疗瘀血阻滞证肝硬化腹水的疗效观察[J].中国现代医生，2017，55（3）：113-116.
[18] 付世阳.一贯煎加味治疗肝硬化腹水（肝肾阴虚证）的临床观察[D].长春：长春中医药大学，2014.
[19] 甘大楠，杜宏波，池晓玲，等.自拟益气活血方治疗乙肝肝硬化腹水气虚血瘀证临床疗效与安全性研究[J].世界中医药，2018，13（12）：2980-2986.
[20] 张兴会.杞地软坚消臌汤加服醋甘遂胶囊治疗肝肾阴虚型肝硬化腹水26例[J].中西医结合肝病杂志，2013，23（5）：305-306.
[21] 魏莹莹.肝硬化自发性细菌性腹膜炎预后分析及中医证型与相关指标的研究[D].北京：北京中医药大学，2018.
[22] 张静，曹艳丽.中西医结合治疗肝肾阴虚型病毒性肝硬化腹水[J].光明中医，2013，28（2）：342-343.
[23] 徐佳娜.五苓散加减治疗乙肝肝硬化腹水临床疗效分析[J].中国医药科学，2018，8（17）：86-88，100.
[24] Wang Z，Li Q，Xiang M，et al. Astragaloside alleviates hepatic fibrosis function via Par2 signaling pathway in diabetic rats [J]. Cell Physiol Biochem，2017，41（3）：1156-1166.
[25] Wang ZC，Yang S，Huang JJ，et al. Effect of bone marrow mesenchymal stem cells on the Smad expression of hepatic fibrosis rats [J]. Asian Pac J Trop Med，2014，7（4）：321-324. |
|
|
|
